Comparative impact of AAV and enzyme replacement therapy on respiratory and cardiac function in adult Pompe mice
Pompe disease is an autosomal recessive genetic disorder characterized by a deficiency of the enzyme responsible for degradation of lysosomal glycogen (acid α-glucosidase (GAA)). Cardiac dysfunction and respiratory muscle weakness are primary features of this disorder. To attenuate the progressive...
Main Authors: | Darin J Falk, Meghan S Soustek, Adrian Gary Todd, Cathryn S Mah, Denise A Cloutier, Jeffry S Kelley, Nathalie Clement, David D Fuller, Barry J Byrne |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2015-01-01
|
Series: | Molecular Therapy: Methods & Clinical Development |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050116300195 |
Similar Items
-
AAV9-TAZ Gene Replacement Ameliorates Cardiac TMT Proteomic Profiles in a Mouse Model of Barth Syndrome
by: Silveli Suzuki-Hatano, et al.
Published: (2019-06-01) -
13C/31P MRS Metabolic Biomarkers of Disease Progression and Response to AAV Delivery of hGAA in a Mouse Model of Pompe Disease
by: Celine Baligand, et al.
Published: (2017-12-01) -
AAV Gene Therapy Utilizing Glycosylation-Independent Lysosomal Targeting Tagged GAA in the Hypoglossal Motor System of Pompe Mice
by: Brendan M. Doyle, et al.
Published: (2019-12-01) -
Hypoglossal neuropathology and respiratory activity in Pompe mice
by: Kun-Ze eLee, et al.
Published: (2011-06-01) -
Increased mtDNA Abundance and Improved Function in Human Barth Syndrome Patient Fibroblasts Following AAV-<i>TAZ</i> Gene Delivery
by: Silveli Suzuki-Hatano, et al.
Published: (2019-07-01)